thymidine has been researched along with Viremia in 9 studies
Viremia: The presence of viruses in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 7.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "To investigate the efficacy and safety of telbivudine for blocking mother-to-child transmission of hepatitis B virus (HBV) in pregnant women with high viremia." | 7.81 | [Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia]. ( Hao, A; Li, M; Liu, W; Ma, L; Song, M; Sun, W; Xin, Y, 2015) |
| "This study indicates that newer antivirals are effective and safe in HTR with CHB." | 5.43 | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. ( Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016) |
| "To observe the success rate of telbivudine (LdT) for the prevention of perinatal transmission of hepatitis B virus (HBV) and the incidence of alanine aminotransferase (ALT) elevation during LdT treatment and after LdT withdrawal in HBV-infected pregnant woman with high viremia in immune-tolerant phase and receiving LdT treatment at the end of pregnancy, and to evaluate the efficacy of LdT in the prevention of perinatal transmission and the safety for pregnant women." | 3.83 | [Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal]. ( Bai, H; Ding, Y; Dou, XG; Fan, YX; Han, C; Li, BJ; Li, YW; Sheng, QJ; Zhang, C, 2016) |
| "To investigate the efficacy and safety of telbivudine for blocking mother-to-child transmission of hepatitis B virus (HBV) in pregnant women with high viremia." | 3.81 | [Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia]. ( Hao, A; Li, M; Liu, W; Ma, L; Song, M; Sun, W; Xin, Y, 2015) |
| " We studied longitudinally 18 hepatitis B e antigen (HBeAg)-positive patients undergoing treatment with direct antivirals (telbivudine or lamivudine) to determine the relationship between treatment-induced viremia reduction and HBeAg seroconversion with respect to PD-1 levels and T-cell reactivity." | 3.74 | Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. ( Brett, S; Chokshi, S; Cooksley, H; Evans, A; Naoumov, NV; Nathwani, A; Phillips, S; Puranik, S; Riva, A, 2008) |
| "This study indicates that newer antivirals are effective and safe in HTR with CHB." | 1.43 | Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. ( Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gerlich, WH | 1 |
| Dunkelberg, JC | 1 |
| Berkley, EM | 1 |
| Thiel, KW | 1 |
| Leslie, KK | 1 |
| Sun, W | 1 |
| Ma, L | 1 |
| Hao, A | 1 |
| Liu, W | 1 |
| Song, M | 1 |
| Li, M | 1 |
| Xin, Y | 1 |
| Durante-Mangoni, E | 1 |
| Vitrone, M | 1 |
| Parrella, A | 1 |
| Andini, R | 1 |
| Iossa, D | 1 |
| Ragone, E | 1 |
| Falco, E | 1 |
| Maiello, C | 1 |
| Utili, R | 1 |
| Zampino, R | 1 |
| Sheng, QJ | 1 |
| Ding, Y | 1 |
| Li, BJ | 1 |
| Bai, H | 1 |
| Zhang, C | 1 |
| Han, C | 1 |
| Fan, YX | 1 |
| Li, YW | 1 |
| Dou, XG | 1 |
| Evans, A | 1 |
| Riva, A | 1 |
| Cooksley, H | 1 |
| Phillips, S | 1 |
| Puranik, S | 1 |
| Nathwani, A | 1 |
| Brett, S | 1 |
| Chokshi, S | 1 |
| Naoumov, NV | 1 |
| Coppola, N | 1 |
| Masiello, A | 1 |
| Tonziello, G | 1 |
| Macera, M | 1 |
| Iodice, V | 1 |
| Caprio, N | 1 |
| Pasquale, G | 1 |
| Bruland, T | 1 |
| Lavik, LA | 1 |
| Dai, HY | 1 |
| Dalen, A | 1 |
| Ross, L | 1 |
| Scarsella, A | 1 |
| Raffanti, S | 1 |
| Henry, K | 1 |
| Becker, S | 1 |
| Fisher, R | 1 |
| Liao, Q | 1 |
| Hirani, A | 1 |
| Graham, N | 1 |
| St Clair, M | 1 |
| Hernandez, J | 1 |
1 review available for thymidine and Viremia
| Article | Year |
|---|---|
Hepatitis B and C in pregnancy: a review and recommendations for care.
Topics: Antiviral Agents; Breast Feeding; Cesarean Section; Contraindications; DNA, Viral; Female; Hepatitis | 2014 |
8 other studies available for thymidine and Viremia
| Article | Year |
|---|---|
Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy.
Topics: Adenine; Antiviral Agents; DNA, Viral; Female; Guanine; Health Personnel; Hepatitis B e Antigens; He | 2014 |
[Predictive value of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women with high viremia].
Topics: Female; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Humans; Immunoglobuli | 2015 |
Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; Guanine; Heart | 2016 |
[Telbivudine for prevention of perinatal transmission in pregnant women infected with hepatitis B virus in immune-tolerant phase: a study of efficacy and safety of drug withdrawal].
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Infant; In | 2016 |
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Topics: Adult; Alanine Transaminase; Antigens, CD; Antiviral Agents; Apoptosis Regulatory Proteins; Biopsy; | 2008 |
[Icteric hepatitis in a patient with non-Hodgkin's lymphoma treated by rituximab-based chemotherapy].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiviral Ag | 2010 |
Identification of Friend murine retrovirus-infected immune cells and studies of the effects of sex and steroid hormones in the early phase of infection.
Topics: 3T3 Cells; Animals; CD8-Positive T-Lymphocytes; Cell Division; Dexamethasone; Female; Flow Cytometry | 2003 |
Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; H | 2001 |